Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

Of 1774 patients with breast cancer given mitoxantrone (MTZ) with methotrexate (n = 492) or with methotrexate and mitomycin C (n = 1282), nine developed MDS/AML after a median of 2.5 years. Median duration of survival from diagnosis of MDS/AML was 10 months and six patients died. The crude incidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Saso, R, Kulkarni, S, Mitchell, P, Treleaven, J, Swansbury, G J, Mehta, J, Powles, R, Ashley, S, Kuan, R, Powles, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374543/
https://www.ncbi.nlm.nih.gov/pubmed/10883674
http://dx.doi.org/10.1054/bjoc.2000.1196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2374543/
https://www.ncbi.nlm.nih.gov/pubmed/10883674
http://dx.doi.org/10.1054/bjoc.2000.1196

Ejemplares similares